Wegovy Pill vs Mounjaro: Full Comparison Guide

Mounjaro and Wegovy pills sit on opposite corners of the GLP-1 map. Wegovy pills deliver semaglutide as a once-daily tablet approved for weight management. Mounjaro delivers tirzepatide as a once-weekly injection approved for type 2 diabetes. Different molecules, different formats, different approvals — yet they're constantly compared because both can produce dramatic weight change.

One hormone vs two

Semaglutide mimics GLP-1, the fullness hormone. Tirzepatide mimics GLP-1 and GIP, a second gut hormone — a dual action that's part of why tirzepatide posts some of the largest trial numbers in the class. We look at the molecule itself in Wegovy pill vs tirzepatide, and at its weight-management brand in Wegovy pill vs Zepbound.

Approvals point in different directions

Mounjaro's FDA approval is for type 2 diabetes; prescribing it purely for weight loss is off-label, which usually complicates insurance and supply. Wegovy pills are approved for chronic weight management in adults with BMI 30+, or 27+ with a weight-related condition — the exact use most people comparing these drugs actually want.

Results in context

Tirzepatide's weight-management trials reported average losses of roughly 15–21% depending on dose — impressive numbers. Oral semaglutide's 64-week study averaged 14% (about 33 lb), with 1 in 4 participants losing 20% or more. On paper tirzepatide edges ahead at top doses; in real life, adherence often decides more than the molecule. A daily pill you take beats a weekly injection you abandon — and injections remain the most cited reason people quit GLP-1 therapy.

Practical differences

Which fits your situation?

If you have type 2 diabetes, Mounjaro is a conversation for your treating physician. If your goal is weight loss without needles, without off-label workarounds, and without four-figure monthly costs, Wegovy pills check every box. Book a free online consultation — a licensed doctor reviews your history, and if approved, your prescription is issued in 10–15 minutes with same-day shipping. You're only charged after approval.

The insurance and off-label reality

On paper, Mounjaro's trial numbers are attractive; in practice, access tells a different story. Insurance plans typically cover Mounjaro only with a documented type 2 diabetes diagnosis, and prior-authorization requirements have tightened as demand exploded. Weight-loss patients pursuing it off-label usually face full list price — commonly above $1,000 monthly — plus pharmacy stock lotteries during shortage stretches. That's the context that makes a flat, always-available $149/month pill plan compelling even against a molecule with bigger headline percentages: treatment you can reliably obtain beats treatment you fight for monthly.

Switching from Mounjaro to Wegovy pills

Patients do make this move — after coverage changes, supply frustration, or injection fatigue — but it's a doctor-managed transition, not a self-serve swap. Tirzepatide and semaglutide are different molecules with different titration ladders, so a clinician plans the handoff timing and starting dose to keep appetite control continuous. If you're currently on Mounjaro and considering the switch, disclose your full dosing history during the consultation; it's exactly the situation our licensed doctors handle in check-ins, included in every plan.

One final practical note: whichever molecule you land on, commit to it for a fair trial window. GLP-1 therapies reveal their full effect over months of titration, and bouncing between medications too early wastes the adjustment period your body has already banked. Pick with your doctor, then give the choice room to work.